Details of the Drug

General Information of Drug (ID: DMJUVE6)

Drug Name

Bulevirtide

Synonyms

Lipopeptide

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis D virus infection	1E51.2	Approved	[1]

Drug Type

Peptide

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 351 +/- 72 mcgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 6.13 +/- 1.29 mcg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 8.4 +/- 3.6 h [2]
Bioavailability: The bioavailability of drug is 64-90% [2]
Clearance: The clearance of drug is 7.98 L/h [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4 - 7 hours [4]
Metabolism: The drug is metabolized via peptidases to smaller peptides and amino acids [3]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/bile acid cotransporter (SLC10A1)	TTWZRY5	NTCP_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03852719) Phase 3 Study of Bulevirtide in Patients With CHD. U.S. National Institutes of Health.
2	FDA Approved Drug Products: Conjupri Levamlodipine Oral Tablets
3	EMA Public Assessment Report: Hepcludex (bulevirtide) powder for injectable solution
4	EMA Summary of Product Characteristics: Bulevirtide
5	Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)